Navigation Links
Hard-to-treat Myc-driven cancers may be susceptible to drug already used in clinic
Date:12/14/2012

PHILADELPHIA Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.

"More than 1 million people diagnosed with cancer each year have a tumor driven by alterations in the Myc gene," said Grant A. McArthur, M.D., Ph.D., professor of translational research at the Peter MacCallum Cancer Centre in Melbourne, Australia. "However, it has proven impossible to develop drugs that effectively target Myc.

"One of Myc's functions is to regulate cell growth. Because mTORC1 is also a regulator of cell growth, we hypothesized that inhibiting mTORC1 with the drug everolimus might suppress Myc-driven tumor initiation and growth."

McArthur and his colleagues tested their hypothesis in a mouse model of Myc-driven lymphoma and found that treatment with everolimus provided strong protection against disease: only four of 33 mice treated with everolimus developed lymphoma, while 22 of 34 mice treated with placebo developed the disease.

In addition, treatment with everolimus led to tumor regression and significantly improved survival compared with placebo in mice with established lymphomas. However, all of these mice eventually relapsed as a result of the growth of lymphoma cells resistant to the effects of everolimus.

"These data confirmed our hypothesis that mTORC1 inhibition could suppress Myc-driven tumor initiation and growth," said McArthur. "The surprise was found in how mTORC1 inhibition led to tumor regression. We had expected that it would trigger cancer cells to die by a cellular process known as apoptosis, but we found that this was not the case."

Detailed analysis of the tumors indicated that everolimus caused tumor regression by inducing cellular senescence.

According to McArthur, normal cells protect themselves when cancer-driving genes are switched on is by entering a state called senescence. When cancers develop, they have found ways to overcome this safeguard. "Our data indicate that one way in which cancers bypass senescence, in particular senescence induced by Myc, is through a signaling pathway involving mTORC1," he said.

Resistance to everolimus treatment in mice with established lymphomas was associated with loss of the function of p53, a protein known to help suppress tumor formation and growth.

"The loss of effectiveness of everolimus therapy against lymphoma cells deficient in p53 function has important clinical implications," said McArthur. "Everolimus could be a useful new string to the bow for clinicians treating patients with Myc-driven cancers, in particular B cell lymphomas, but that it would be helpful only to those patients with functional p53."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
2. NY-Presbyterian Hospital announces participation in trial for hard-to-treat hypertension
3. Caffeinated coffee may reduce the risk of oral cancers
4. Vanderbilt study finds diverse genetic alterations in triple-negative breast cancers
5. More Cancers May Be Missed Under Latest Mammogram Guidelines
6. A*STAR scientists identify potential drug target for inflammatory diseases including cancers
7. Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
8. PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
9. Study: Repeated surgeries appear to extend life of patients with deadliest of brain cancers
10. Green tea found to reduce rate of some GI cancers
11. Assessment of HPV DNA alone insufficient to identify HPV-driven head and neck cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... “Vintage and ... a retired minister and college Bible teacher residing in North Carolina with his wife, ... who have blessed them with six grandchildren. David is also the author of “Shadow ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating ... communities, 16 more public health departments have been awarded national accreditation through the ... million people into the expanding network of communities across the nation whose health ...
(Date:3/23/2017)... ... 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the way ... impact on businesses and individual consumers alike. Laboratories can maximize their profit margin ... anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... families and businesses of the Norwalk and Vermillion areas, celebrates the newest ... (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and peer recovery support ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... PARSIPPANY, N.J. , March 23, 2017 /PRNewswire/ ... ) (the "Company"), a fully integrated commercial company ... pathology services, today announced that it has entered ... with the former RedPath Shareholders ("RedPath") and concurrently ... The Company,s outstanding secured debt to RedPath ...
(Date:3/23/2017)... LITTLE SILVER, N.J. , March 23, 2017 ... device company, today announced that it has kicked ... in-growth into their 3D printed bone segments. ... of Engineering, "Our unique variable honeycomb lattice structures ... bone in-growth as compared to current allograft wedges ...
(Date:3/23/2017)... 2017 Newborns are highly vulnerable to ... because their young immune systems typically mount weak ... report achieving strong vaccine responses in newborn animals, ... human trials — by adding compounds known as ... simultaneous papers, they also describe improved adjuvant formulations ...
Breaking Medicine Technology: